-+ 0.00%
-+ 0.00%
-+ 0.00%

Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting

Benzinga·11/04/2026 14:06:21
Diffusion vocale

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans. The presentation has also been selected for ASH’s official press program. Risto-cel is an investigational autologous genetically modified cell therapy being evaluated for the treatment of SCD.